CSTL — Castle Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $561.12m
- $318.12m
- $219.79m
- 83
- 42
- 74
- 73
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 5.28 | -10.3 | -31.3 | -67.1 | -57.5 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 1.34 | 10.5 | 21.7 | 16.8 | 46.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.044 | 9.15 | -4.1 | -0.007 | -6.63 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 7.01 | 9.87 | -19 | -41.7 | -5.63 |
Capital Expenditures | -0.937 | -4.75 | -3.48 | -5.63 | -13.6 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | 0.003 | -63.2 | -161 | -2.56 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.937 | -4.75 | -66.7 | -167 | -16.2 |
Financing Cash Flow Items | 0.218 | 1.61 | 1.2 | 0.804 | -2.42 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 88.3 | 306 | 5.42 | 1.51 | -2.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 94.4 | 311 | -80.2 | -207 | -24.1 |